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Alexander Pomeroy: The Effect of Blood Pooling in the Lower Limbs During Prolonged Sitting 
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(Under the direction of Lee Stoner) 
 
Prolonged sitting (PS) can induce arterial stiffening, which is a precursor of 
atherosclerosis of the cerebral arteries. Heart-Middle Cerebral Artery pulse wave velocity 
(hmPWV) was assessed in eleven participants were examined over two randomized cross-over 
trials (SIT: n = 5, 23.6 [5.3] y, 40% F, 23.1 [3.2] kg/m2; LAY: n = 6, 26.5 [7.6] y, 66.7% F, 22.5 
[2.3]). Participants underwent two conditions on two separate visits in each trial: Cuff, where 
bilateral occlusive cuffs were applied to the legs and Non-Cuff, a control condition. In the Cuff 
and Non-Cuff conditions in each trial, hmPWV decreased over time. In the SIT trial, the random 
effects model generated a large time effect (ß = -97.17, 95% CI: -125.1 to -69.28, ES = 1.55). 
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CHAPTER I: INTRODUCTION 
 
Vascular Dementia (VaD) affects an estimated 4% of U.S. seniors (65+ years old),1 and 
increases to 15% for those 80+ years old.2 One of the major risk factors for development of VaD 
is atherosclerosis, specifically in the cerebral arteries.3–5 While several factors can contribute to 
atherosclerotic development, hemodynamic causes, including acute arterial stiffening, have been 
suggested to have the greatest contribution.6 Cerebral arterial stiffening, including that due to 
atherosclerosis, also increases with age.7,8 During a bout of prolonged sitting (uninterrupted 
sitting greater than 1 hour in duration), central and peripheral arterial stiffening is well-
documented.9,10 It has been hypothesized that venous pooling in the lower limbs (VP), a 
phenomenon known to occur during prolonged sitting, contributes to the observed disruptions to 
central hemodynamics.11 However, the physiological relationships potentially linking cerebral 
hemodynamic changes and venous blood pooling has not been thoroughly investigated. If these 
relationships are better understood through research, treatments could be developed that target 
this relationship, potentially reducing an individual’s rate of cerebral atherosclerotic 
development. 
 
This study aimed to elucidate the relationship between VP during an acute bout of 
prolonged sitting and changes in cerebral hemodynamics, and determine how much VP 
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contributes to cerebral hemodynamic changes during sitting. In the long-term, establishment of a 
potential mechanism would allow researchers to study the mechanism in vulnerable populations, 
such as those at risk for cerebrovascular dysfunction, and come up with sitting interruption 
strategies. This study is novel, as there is limited evidence into the role of venous pooling in 
affecting cerebral arterial function. While this study did not seek to establish sitting interruption 
strategies for cerebral hemodynamic disruptions, a mechanism could inform future studies of 
what physiological variables need to be addressed in the development of interruption strategies. 
 
The primary hypothesis for this study was that VP causes arterial stiffening in the 
cerebral arteries. To test the hypothesis, the study assessed arterial stiffness during a bout of 
prolonged sitting, and during a bout of prolonged sitting with a sub-diastolic tourniquet to 
augment VP. Changes in arterial stiffness and VP were compared between conditions and over 
time within-subjects. 
Aim 1: Determine the effect of venous pooling manipulation on the cerebral arterial 
stiffening response. 
Six healthy, young adults were recruited for study in the first randomized crossover trial. The 
participants completed the first trial (LAY), with a control session of two hours uninterrupted 
supination (2 hours, CONTROL), and an experimental condition with increased venous pooling 
via dual, bilateral tourniquets inflated that fully occluded the calves (CUFF). 
The primary outcome was cerebral arterial stiffness (AS) and the independent variable was 






1. In the condition with bilateral leg tourniquets, VP would increase beyond that measured in the 
control condition, and cerebral AS would beyond what would be measured in the control 
condition. 
 
Aim 2: Determine the effect of venous pooling manipulation during a bout of prolonged 
sitting on the cerebral arterial stiffening response. 
Six healthy, young adults were recruited for study in the second randomized crossover trial. The 
participants would complete the second trial (SIT), consisting of a control session of prolonged 
sitting (2 hours, CONTROL), and prolonged sitting with dual, bilateral tourniquets inflated that 
fully occlude the calves (CUFF). 
The primary outcome was cerebral arterial stiffness (AS) and the independent variable was 
venous pooling (VP). Mechanistic outcomes provided context to the relationship. 
Research hypotheses: 
1. During a bout of prolonged sitting, VP would increase, and cerebral AS would increase. 
2. In the condition with bilateral leg tourniquets, VP would increase beyond that measured in the 
respective control condition, and cerebral AS would increase beyond what would be measured in 
the control condition. Both VP and cerebral AS in the prolonged sitting trial CUFF condition 








ASSUMPTIONS, DELIMITATIONS & LIMITATIONS 
Assumptions 
 
• Participants accurately follow pre-assessment guidelines and give truthful information to 
questionnaires. 
• Placement of devices, such as Transcranial Doppler (TCD) and fNIRS, was similar 
between the two visits. 
Delimitations 
 
• Experimental visits occurred at the same time of day to mitigate diurnal effects. 
• Participants were fasted for 8 hours to reduce the influence of glycemic hormones. 
Limitations 
 
• TCD probe placement may have varied slightly between visits. 
• To reduce participant burden, the length of the sitting bout was set at 2 hours of sitting. It 
is possible that this duration may not elicit as large of a change in the function of the 




CHAPTER II: REVIEW OF LITERATURE 
 
INTRODUCTION TO TOPIC 
 
The purpose of this literature review is to summarize the current knowledge related to 
prolonged sitting and acute deficits in cerebrovascular function, and explain why this research 
points to the value of establishing a mechanism for cerebral hemodynamic disturbances. 
Atherosclerosis of the cerebral arteries can develop in arteries exposed to high pulse pressure,12 
which occurs when arteries undergo acute stiffening.13 Arterial stiffening can be observed by 
elevated pulse wave velocity (PWV) through an arterial segment.14 Studies have shown aortic 
PWV elevations of 0.3-0.4 m/s after 3 hours of prolonged sitting.9,10 While this does not directly 
reflect changes in the cerebral arteries, changes in aortic PWV have been previously correlated to 
changes in cerebral arterial stiffening as measured by pulsatility index.15 However, the 
mechanism for how these changes occur during sitting is unclear. With limited knowledge of a 
mechanism, physiologists are unable to establish guidelines for to reduce sitting exposure for 
people, especially those in at-risk populations. The literature review explains the basis for 
investigation into the role of prolonged sitting and its effect on cerebral arterial stiffening, as well 
as exploratory analysis into the impact of potential cerebral hemodynamic changes on executive 








Sedentary behavior is behaviors that are 1.5 metabolic equivalents (METs) or less while 
awake, and includes standing still, laying, and most forms of sitting.16 Sedentary behavior is 
different than being physically inactive,16 and is considered a separate risk factor for 
cardiovascular17 and cerebrovascular18 diseases. Time spent in sedentary behavior is a risk even 
in those who are highly physically active,19 showing that there is a need to address its risks in all 
sedentary populations. In western countries, time spent sedentary for adults is increasing. 





































1992 to 2006, non-occupational sedentary time has stayed stable, but 90% of non-occupational 
time was spent in sedentary behavior.21 In combination, these stats show in a steady rise in time 
spent sedentary, which means people are exposed to an increasing amount of risk for 
cerebrovascular disease. Fortunately, sedentarism is a modifiable lifestyle factor. While some 
risk factors for cardiometabolic disorders are based on genetics or uncontrollable variables,22 
modifiable lifestyle factors can be altered by changing present behaviors to healthier ones. For 
example, instead of participating in uninterrupted sedentary behavior, a person could break up a 
single bout by getting up and walking or doing light exercise.23 Strategies to mitigate the effects 
of sedentary behavior are most limited by a lack of knowledge about its effects and mechanisms, 
as it wasn’t clearly defined until 2017.16 
 
GAPS IN KNOWLEDGE 
 
While sedentary behavior has been linked to a variety of vascular pathologies, including 
cerebral atherosclerosis, there is still a lot of physiological information to be discovered, which 
could indicate the aspects of sedentary behavior that have the greatest impact on disease 
developments. This study assessed one aspect of prolonged sitting, a prevalent form of sedentary 




Executive function describes a wide variety of cognitive behaviors, ranging from control 
of attention to reasoning and working memory.24 Most executive functions are impulses that 
originate in the prefrontal cortex,24 and are considered higher-order thought processes.25 These 
processes are critical for all life activities, including activities of daily living and occupational 
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attentiveness,26 to name a few. Executive function can be altered by behaviors such as exercise,27 
and events such as ischemic brain injury.28  
 
Healthy executive function is heavily reliant on a process known as neurovascular 
coupling.29 Neurovascular coupling is a process by which the brain sends nutrients to active 
regions of the brain based on their metabolism.30 For example, while performing a pattern-
recognition task, which would require processing from the frontal lobe,24 metabolism of oxygen 
and glucose by the frontal lobe would increase, and neurons would signal local arterioles to 
dilate and perfuse more blood to the tissue.30 Because of the relationship between brain function 
and neurovascular coupling, functional outcomes, such as performance tests,29 can provide 
evidence for healthy or dysregulated cerebral hemodynamic function. 
 
An important covariate of executive function is sleep.31 After an acute bout of sleep 
deprivation, a group was found to perform worse on a Spatial Stroop task, which involved 
participants looking at a blank screen until a left or right-pointing arrow appeared, then required 
them to press the corresponding arrow key on a keyboard. The group saw an increase in both 
time to completion and number of errors.32 Some people naturally sleep more or less,33 but acute 
changes in sleep duration were used to covary with executive function changes. Furthermore, 
sleep quality can influence executive function measures.34 Both can be measured with 








Executive function changes are one potential consequence of cerebral hemodynamic 
changes. In the proposed study, executive function was assessed to determine the functional 
impact of prolonged sitting on participants. 
 
HEMODYNAMIC PRECURSORS OF CEREBRAL ATHEROSCLEROSIS 
 
Atherosclerosis is a gradual process that can occur in the arteries, and the middle cerebral 
artery, one of the primary arteries delivering blood to the cerebrum, is particularly vulnerable.36 
While genetic37 and metabolic38 factors can contribute to this process, hemodynamic factors may 
play a larger role in atherosclerotic development.17 Two hemodynamic contributors to 
atherosclerosis that can occur in the cerebral vasculature are exposure to acute arterial 
stiffening14 and decreased cerebral blood flow.39 Both work synergistically to contribute to 
atherosclerosis by exposing the cerebral arteries to potentially damaging pulse pressures14 and 
promoting dysfunction of the arterial endothelium in cerebral arteries via a reduction in shear 
stress respectively.17,40,41 
 
High arterial stiffness in the carotid artery has been shown to be associated with increased 
atherosclerosis of the intracranial cerebral arteries.42 Healthy arteries are not stiff, instead being 
highly elastic, and absorb some of the pulse pressure by way of the Windkessel effect.41 This 
effect is highly dependent on the function of the arterial endothelium.41 When exposed to high 
pulse pressures, the function of the endothelium can be impaired, and begins to constrict the 
blood vessels.43,44 These damages stimulate thickening in the arterial wall which can be pro-
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atherosclerotic in the cerebral arteries,41 and with continued exposure can lead to remodeling of 
the arterial wall.36,41 This remodeling can include atherosclerotic development.36,43 
 
Decreases in cerebral blood flow (CBF) could mediate the changes in pro-atherogenic 
endothelial dysfunction that occurs with arterial stiffening.45 The function of the arterial 
endothelium is dependent on the shear stress on the innermost layer of the blood vessel.40,41 
When arteries are subjected to decreased flow, the endothelium will constrict the artery.41 In 
healthy individuals, total CBF is controlled by a process known as cerebral autoregulation 
(CAR).46 Due to variance in blood pressure throughout the day, the cerebral arteries adapt to 
maintain a continuous supply of oxygen and glucose to the brain.46 However, the cerebral 
autoregulatory system responds effectively to changes in mean arterial pressure (MAP, a 
weighted average of systolic and diastolic blood pressures), but it does not respond as well to 
changes in systolic pulse pressure alone.44 When arteries are subjected to high pulse pressures, 
the autoregulatory system will stimulate the cerebral arteries to constrict,44 even though MAP 
may not be increasing at the same rate. If arteries are constricting, but MAP is not increasing 
proportionally, shear stress on the arterial wall would decrease,41 and therefore the arterial 
endothelial function can become dysregulated. Repeated exposure to endothelial dysfunction is 
associated with atherosclerosis in central arterial tissues,6 but it has not been thoroughly explored 
in cerebral arteries. However, in an elderly population, higher resistance to flow, which could be 
due to arterial stiffening, was associated with decreased blood flow through the middle cerebral 
artery.47 The combination of increased cerebral arterial stiffening and decreased CBF provide a 
physiological pathway by which local endothelial dysfunction creates a pro-atherosclerotic state 
in the cerebral vasculature. 
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GAPS IN KNOWLEDGE 
 
The specific aspects of prolonged sitting that impact CBF are not well understood. 
Understanding how CBF changes could indicate a mechanistic connection between prolonged 
sitting changes and atherosclerosis development risk. This study aims to assess how CBF is 
impacted by prolonged sitting. 
 
PROLONGED SITTING ACUTELY IMPAIRS CEREBROVASCULAR FUNCTION 
 
During an acute bout of prolonged sitting, acute hemodynamic changes have been 
observed related to both arterial stiffening48,49 and cerebral blood flow.48,50 The effects were 
observed after 2-4 hours of sitting in the cited studies. However, the aspects of sitting that 
contribute to these changes have yet to be identified, and the rate at which they contribute is 
unknown.  
 
Currently, evidence has shown a relationship between indicators of systemic arterial 
stiffening in the cerebral vasculature and sitting time.48,49 However, investigation into stiffening 
of specific cerebral arteries is limited. Furthermore, the evidence for central arterial stiffening is 
during prolonged sitting is well-established.9,10 While this does not directly point to a 
relationship between prolonged sitting and cerebral arterial stiffening, there is evidence that 
increased central arterial stiffness is correlated with increased stiffness in the common carotid 
artery,51 which are the primary arteries that supply blood to the head and neck as a whole.52 
There is also evidence that higher stiffness in the aorta is correlated with higher systemic 
stiffness of the cerebral arteries.15 While there is not much evidence of a direct relationship 
between prolonged sitting and stiffening in the cerebral arteries, there are connections between 
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prolonged sitting and central arterial stiffening, and central arterial stiffening and cerebral arterial 
stiffening that point to an indirect relationship at least. 
 
Cerebral blood flow has also been shown to decline during a bout of prolonged sitting. In 
two studies with 2- and 4-hour sitting bouts, mean cerebral blood velocity was shown to decrease 
by 2.2 and 1.8 cm/s, respectively.48,50 Mean cerebral blood velocity can be used to assess 
changes in cerebral blood flow.50 In general, periods of increased blood flow upregulate function 
of the vascular endothelium,53 and periods of decreased blood flow are associated with 
endothelial dysfunction.54,55 While the rate of endothelial dysfunction caused by changes in 
cerebral blood flow is not clear, a repeated cross-sectional study showed a negative association 
between cerebral blood flow and blood markers of endothelial dysfunction over a 33 year 
period.56 Since endothelial dysfunction is a precursor for atherogenesis in the cerebral arteries,36 
cerebral blood flow decreases could also contribute to the rate of atherogenesis. 
 
Lastly, the acute cerebrovascular dysfunction from prolonged sitting may result in 
changes in cognitive performance, demonstrating the connection between vascular and end-
organ function. A cross-sectional study showed lower scores of executive function tests have 
also been linked to higher stiffness of the carotid arteries,57 which supply blood to the head and 
neck. Furthermore, changes in executive function decreases during sitting have been thoroughly 
researched, though largely in older adults.27,58 A connection between executive function and 





GAPS IN KNOWLEDGE 
 
While there is evidence for decreased cerebral blood flow during sitting, less has been 
done to establish the contributions of arterial stiffening that occurs during a single bout of sitting. 
Arteries become stiffened due to multiple physiological stimuli, and upon repeated exposure, can 
then become atherosclerotic. Evidence for a mechanism for cerebral arterial stiffening, mediated 
by changes in cerebral blood flow, would help determine how much and when sitting becomes 
pathological, and help experts to design strategies to mitigate these pathologies. 
 
MECHANISM FOR CEREBROVASCULAR CHANGES DUE TO GRAVITATIONAL BLOOD 
POOLING 
 
The cardiovascular system is complex, and relies on three mechanisms to generate 
pressure that drives blood through the body: the heart, the respiratory pump, and the skeletal 
muscle pump.60 Healthy function helps the body to deliver blood to all tissue as needed despite 
various forces that may act on the body throughout the day, including gravity. However, during 
an acute bout of sitting the role of the skeletal muscle pump is diminished due to decreased 
skeletal muscle activity. The heart and respiratory pump increase effort to compensate for the 
lack of muscle pump activity, but are unable to fully compensate for the reduction of blood 
pressure generation.11 Therefore, gravity causes blood to pool in the veins of the lower limbs,61 
which are the lowest point on the body while sitting, and the farthest anatomical distance away 
from the heart. The longer this continues, the more blood pools. A study was conducted that 
showed blood pooling in the calves at 5.3 mL per 100 mL total blood after 5 hours.11 If blood 
continues accumulating in the calves, it means less blood is available to return to the heart. 
Decreased return of blood to the heart is synonymous with decreased preload.62 Preload is a 
determinant of stroke volume in the heart, and a decrease in preload results in a decreased stroke 
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volume. Stroke volume is also a determinant of cardiac output, meaning cardiac output declines 
proportionally.62 I hypothesize that a decrease in cardiac output results in two synergic pathways 
in the cerebral arteries occur during an acute bout of sitting. 
 
The decrease in cardiac output causes a decrease in central blood pressure.63 The decrease 
in central blood pressure is detected by baroreceptors in the carotid artery,64 which then trigger a 
release of catecholamines throughout the body.64 These catecholamines constrict arteries 
throughout the body, including the cerebral arteries.65,66 Once constricted, the ability of the 
arteries to dampen pressure waves via the Windkessel effect is reduced.67 This means the 
cerebral arteries experience a greater pressure wave from the heart, which result in damage and 
remodeling.68 During arterial remodeling from an acute bout of sitting, it is possible that 
atherosclerotic changes are made that can accumulate over time.69 
 
Furthermore, the decrease in cardiac output simultaneously decreases the amount of 
blood flowing to the head.70–72 The decrease in brain blood flow likely leads to reduced shear 
stress on the cerebral arterial walls.41 The resulting reduction in shear stress would induce 
endothelial dysfunction,40 particularly at arterial bifurcations more proximal to the brain.41 In this 
way, endothelial damage and dysfunction are promoted by both arterial stiffening and reductions 
in brain blood flow, potentially leading to cerebral arterial atherogenesis. 
 
GAPS IN KNOWLEDGE 
 
While blood pooling during sitting has been observed previously, we aren’t sure of the 
impact of blood pooling on acute cerebrovascular function. There is evidence that blood pooling 
does have some effect on cerebral vascular function via changes in executive function,62 but the 
 
 15 
rates and magnitudes of arterial stiffening and cerebral blood flow changes during an acute bout 
of sitting have not been explored in depth. 
 
WHY IS THIS STUDY NEEDED? 
 
Currently, it is unclear if blood pooling in the calves influences hemodynamic changes in 
the cerebral arteries. If so, treatment strategies targeting blood pooling would allow for the 
changes in cerebral hemodynamics to be reduced or eliminated. Furthermore, no study to date 
has simultaneously assessed each physiological step of the proposed mechanism by which these 
changes occur, including blood pooling, changes in cardiac output, arterial stiffening, and 
cerebral blood flow. These measurements are all steps in the proposed mechanism, and can be 
measured non-invasively. Establishment of a mechanism allows researchers a framework with 
which to conduct future studies on changes that happen throughout the body, and affect the 
cerebral vasculature. 
 
METHODOLOGICAL AND RIGOR CONSIDERATIONS 
STUDY DESIGN CONSIDERATIONS 
 
A multitude of study designs were considered to assess the mechanism of this project. 
The study design needed to consider factors such as participant convenience and ability to 
participate, reduction of influence for potential covariates, and ability of investigators to 
administrate the procedure. Furthermore, the study would need to separate the effects of blood 
pooling from the effects of sitting. A cross-sectional study design would be convenient for 
participants and investigators, but would not allow the degree of investigation into the function 
of the mechanism that would be possible with variable manipulation. A randomized controlled 
trial (RCT) would address the need for manipulation well, and is considered the gold-standard 
for experimental physiological research. However, it would require a large sample size to 
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achieve results, and there are insufficient resources to perform one for this question. Lastly, a 
randomized crossover trial would allow for assessment of the mechanism under two conditions, 
allowing us to make conclusions based on within- and between-subject data. To differentiate 
between the effects of blood pooling and those of sitting alone, two randomized cross-over trials 
were settled on. One cross-over trial had participants lie down with and without cuffs, and the 
other had participants sit without and without cuffs. The two-trial design can inform investigators 
as to the effects of blood pooling in the calves alone, versus the effect of blood pooling combined 
with a bout of sitting. 
 
For the sitting trial, it is worth considering what type of sitting is most ecologically valid. 
Most sitting occurs in a chair, with the knees and hips bent at approximately 90 degrees. 
Therefore, a standardized chair was used. Because a standard chair may not cause each 
participant to sit with the same joint angles, an adjustable set up was needed. An adjustable bed 
could be used that can fold up to form a back and seat in conjunction with an adjustable footrest 
to ensure all participants are sitting similarly to a standard seated posture. Furthermore, the 
adjustable bed could be folded down and used for the lying trial. For this posture, the 
requirement would be to ensure that the participant be lying flat, so as to eliminate any pooling 
due to gravity in any part of the body. The adjustable bed would make both postures achievable. 
 
The randomized cross-over trial model allows each participant to be in a control and 
experimental group, allowing for within-subject comparisons that reduce the influence of 
potential covariates on the data. Measures of cerebral arterial stiffness, brain blood flow, and 
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cognitive function were assessed between Cuff and Non-Cuff visits for each participant, and 




As outlined in Figure 1, there are several steps proposed between venous pooling in the 
lower limbs and cerebrovascular outcomes. In order to provide evidence for the mechanism, as 
many of the proposed steps should be measured as is feasible. However, not all steps can feasibly 
be measured with non-invasive methods. Therefore, multiple measurement techniques are 
considered for each step below, based on the following mechanistic factors: blood pooling in the 
calves, cerebral arterial stiffening, cerebral blood flow, executive function and cognitive load, 
and cardiac output. 
 
INDEPENDENT VARIABLE: BLOOD POOLING 
 
Blood pooling can be assessed via multiple methods. Previous work has shown that calf 
circumference can be used to measure venous distension due to blood pooling73. Near-Infrared 
Spectroscopy (NIRS) can also be used. NIRS can allow for continuous assessment of oxygenated 
hemoglobin concentration, which can be used to assess blood pooling74. While a NIRS 
instrument is more expensive and complex, it would give continuous data compared to a manual 
measurement of calf circumference.  NIRS is also a valid and reliable technique for venous 
pooling measurements75. However, NIRS probes can only be placed on one portion of the calf at 
a time, and do not allow analysis of the whole calf at once. Despite this, continuous data can help 
to show the rate of blood pooling over time, and would be helpful in providing clear evidence of 
a mechanism. Furthermore, the Cardiometabolic Lab (CML) has a NIRS device available to use, 
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so the expense of the device does not apply to this study. Lastly, calf circumference and NIRS 
would not interfere with each other, so they can also both be used. The use of calf circumference 
can serve as a secondary measurement, with a lower opportunity for failure, but no ability for 
continuous measurement. The device redundancy provided more methods for assessing changes 
in the mechanism. 
 
PRIMARY OUTCOME: CEREBRAL ARTERIAL STIFFENING 
 
Arterial stiffening is the primary outcome for this experiment, as it has been directly 
shown to be associated with atherosclerosis of the cerebral arteries.76 The gold-standard for 
measuring clinical arterial stiffness is Pulse Wave Velocity.77 Pulse wave velocity involves the 
measuring of the speed of the pulse pressure generated by the heart through a given arterial 
segment.77 Performing a measurement of pulse wave velocity on an arterial segment more local 
to the area of interest has been shown to be a better predictor of disease more systemic 
measurements.78 The MCA is particularly vulnerable to atherosclerotic development.36 
Therefore, Heart-to-Middle Cerebral Artery pulse wave velocity (hmPWV) can be used to assess 
arterial stiffening in the cerebral arteries. This is a novel method that uses the entire path from 
the aorta, connected to the heart, through the carotid artery, to the middle cerebral artery (MCA), 
one of the most prominent arteries that supplies blood to the brain. hmPWV can be assessed 
using a Transcranial Doppler (TCD), and allowed for non-invasive monitoring of the MCA. 
hmPWV is a relatively novel measure, but has been used in one previous study to be a repeatable 
measure.79 hmPWV was developed to analyze the entire path blood takes to get to the cerebral 
vasculature, and may therefore offer more insight into hemodynamics leading to and including 
the cerebral arteries. 
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SECONDARY OUTCOME: CEREBRAL BLOOD FLOW (CBF) 
 
Changes in cerebral blood flow (CBF) indicate the ability of the brain to respond to brain 
metabolic needs in the presence of hemodynamic disturbances, such as blood pooling. The brain 
is strongly reliant on CAR and NVC to supply enough oxygen and glucose-carrying blood to 
metabolically active regions of the brain.80 Whereas CAR functions at the level of the large 
arteries, including the common carotid artery, NVC functions at the level of the distal cerebral 
arteries and arterioles. Furthermore, both CAR and NVC are hypothesized to be reliant on 
healthy endothelial function in the cerebral arteries and arterioles.80,81 To measure the reactivity 
of both cerebrovascular systems, two related methods were required. The distinction between 
CAR and NVC in the different regions of the cerebral vasculature is illustrated in Figure 2 
below.  
 
Figure 2. Relationship between cerebral processes and vasculature units responsible for function.  
 
Therefore, the methods of measurement should be able to discern the function of these 
two mechanisms to determine the extent of hemodynamic disruption. Doppler ultrasound and 
TCD present potential methods. Doppler ultrasound of the CCA can be used, and has been used 
in the medical field as an assessment of total CBF.82 The CCA is proximal to, but not within the 










brain receives.83 Changes in blood flow through the CCA then provide a good estimate for 
changes in total CBF. Changes in total CBF would help determine CAR functionality, but not 
NVC function. Using TCD to assess mean blood flow velocity through the middle cerebral artery 
(MCA BFV) is a validated method for assessing CBF,84 and has been used widely.85,86 While 
technically only a measure of velocity, rather than volumetric flow, there is evidence that MCA 
BFV varies linearly with volumetric flow with 0.93 agreement compared to magnetic resonance 
imaging (MRI), which can be used to determine volumetric flow, within-subjects over an 
intervention.87 Approximately 80% of the blood for the brain flows through the MCA,87 which 
means that changes in MCA BFV are representative of CBF through the cerebral circulation. 
TCD can also collect MCA BFV and hmPWV simultaneously, which makes taking both 
measures logistically simpler. In this experiment, both CCA CBF and MCA CBF can provide 
data both for CAR and NVC function respectively during the intervention. CCA CBF 
measurements can be taken before and after the intervention, and MCA CBF used as a 




Figure 3. Depiction of the arterial pathway between the heart and brain. 
MCA BFV can also be used with a more specific method for assessing NVC. Established 
methods for measuring changes in NVC, include functional Magnetic Resonance Imaging. 
(fMRI) and functional NIRS (fNIRS). Both are used in “functional” neuroimaging, which 
involves monitoring changes in CBF during a task. fMRI can show blood flow through regions 
of the brain as well as neural activity in those regions.88 However, fMRI is expensive, and due to 
the magnetic field produced, excludes any other measurements from being performed on a 
participant. fNIRS is a more compact, less expensive technology that allows assessment of 














infrared light to determine hemoglobin levels in various regions of the cerebral circulation. It is 
differentiated from NIRS in that it is highly time-sensitive, making it useful for assessing rapidly 
changing cerebrovascular function.89 fNIRS is specific to a certain region of the brain at a time, 
and must be targeted to a desired section of the cerebral vasculature and cannot perform overall 
scans. Despite this, accurate data can be collected if one knows what regions are likely to 
undergo blood flow changes due to NVC. Because we are using performative tests of executive 
function in this experiment, fNIRS can be directed at the frontal lobe, which is responsible for 
most cognitive function.90 fNIRS’s compatibility with other measurements and lower cost can 
justify its use for assessment of NVC. 
 
Lastly, decreased blood flow can result in decreased shear stress in the cerebral arteries. 
Endothelial function is moderated by shear stress on the endothelial wall.40 While measuring 
blood flow through the CCA, shear rate in the artery can be determined using the equation s-1 = 
4 ∗ 𝑉!"#$/𝑑, with Vmean as mean velocity and d as arterial diameter.91 This information is 
calculated automatically by the same software that monitors blood flow, so no extra work is 
needed. The CCA is upstream of the cerebral arteries in terms of blood flow, and changes in 
shear rate at the CCA during prolonged sitting are likely to reflect shear rate changes in cerebral 
vasculature.92 Furthermore, the CCA itself is vulnerable to arterial stiffening and atherogenesis, 
particularly at its bifurcations.92 Most importantly, decreases in cerebral artery shear stress is 






EXECUTIVE FUNCTION (EF) AND COGNITIVE LOAD 
 
To establish a connection between an acute bout of sitting and future cerebrovascular 
complications, a measurement must be made that shows acute cerebrovascular hemodynamic 
changes are associated with acute deficits in cognition. Evidence has shown a strong association 
between stiffening of the carotid57 and middle cerebral93 arteries and poorer scores on executive 
function (EF) tests in cross-sectional studies. Furthermore, EF is related to healthy NVC.94 
However, there is less evidence for the relationship between acute cerebrovascular hemodynamic 
changes and acute cognition changes. To assess these changes, tests for cerebrovascular 
complications such as VaD would be most useful, as they could show the impact of altered 
cerebrovascular hemodynamics on the same areas that develop complications later.  In particular, 
the Trail-Making Test (TMT) and Verbal Fluency Test (VFT) have been used to assess EF,95,96 
and have been used as diagnostic criteria for VaD.97,98 The tests are also logistically simple and 
can be easily administered to participants with only a brief explanation. A test that can be 
quickly administered can lessen participant burden compared to a longer test. Furthermore, the 
TMT uses visual stimuli for assessment, and the VFT uses verbal stimuli. The TMT has 
participants connect circles with letters and numbers inside them by tapping a screen, and is 
scored for time, and the VFT involves articulating words related to a specific prompt for 1 
minute, and is assessed by number of correct words produced. By combining the results of both 
tests, there would be minimal interference due to differences in perceptive ability or stimuli 
processing, better reflecting changes in EF. Ultimately, these tests offer a performative 




In combination with the TMT and VFT, eye tracking can be used to assess relative 
cognitive load. Cognitive load is the amount of working memory being occupied during a given 
task.99 A cognitive load measurement would measure the level of exertion by the brain for a 
given task. There is evidence that cognitive load increases during a given task as regional NVC 
becomes impaired.100 Therefore, an increase in cognitive load during a test of executive function 
could indicate functional NVC impairments. Saccade counts and blink rate are validated, 
logistically simple methods to determine relative cognitive load.101,102 Saccade counts are 
particularly useful during visual-spatial tasks, such as the TMT, and blink rate can be used 
during visual or auditory tests, including the TMT and VFT.101 Saccade counts are measured by 
frequency, with an increasing number indicating higher cognitive load. A higher blink rate would 
also indicate a higher cognitive load. While eye tracking devices are expensive, the CML already 
owns one, which eliminated cost concerns for this method. Eye tracking to determine relative 
cognitive load could add to the relationship between executive function and cerebral 
hemodynamic function during prolonged sitting. 
 
STROKE VOLUME AND CARDIAC OUTPUT (CO) 
 
Lastly, a central aspect of the proposed mechanism involves changes in cardiac output 
(CO). There are multiple methods available for CO measurement, including invasive 
measurements such as catheterization, and non-invasive methods, such as ultrasound monitoring 
of cardiac output and newer devices. While catheterization can be used and has a long history of 
use, it requires high operator skill and an area for sterile medical operations.103 Furthermore, its 
invasive nature could interfere with other measurements in the body. In contrast, ultrasound 
measurements of CO via stroke volume monitoring have been validated against 
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catheterization.104 While ultrasound techniques are well-validated, they cannot obtain continuous 
data. Devices such as the Finapres® can be used to assess CO and stroke volume continuously. 
They acquire a value via the Model Flow method.105 This allows the analysis of stroke volume 
with every heartbeat, and a value for cardiac output when stroke volume is multiplied by heart 
rate per minute.  While the Finapres® can obtain data continuously, the device has not been 
thoroughly validated. These methods are not exclusive, and can both be used simultaneously to 
generate data for the proposed mechanism. Also, the CML already has both Doppler ultrasound 
and trained operators, and owns a Finapres®. Having access to multiple methods justified the 
consideration of the use of these procedures to monitor changes in cardiac output. 
 
PRE-VISIT EXPERIMENTAL VISIT CONTROL 
 
Before testing, participants must ensure they adhere to the pre-assessment guidelines, 
which were as follows: 8 hours fasted except for water; no caffeine, alcohol, or drug use for 12 
hours except prescribed medications; and 24 hours without vigorous exercise. Fasting for 8 hours 
is sufficient to decrease the influence of metabolic hormones on data quality. Caffeine is noted 
for having effects on blood pressure,106 which could confound results. Exercise is known to have 
effects on blood pressure for about 12 hours,107–109 so 24 hours was chosen to be certain it would 
not confound our results. Lastly, participants were asked about their sleep patterns. Acute sleep 
deprivation has been found to affect PWV110 and executive function measures.32 A summary of 








Table 1. Pre-visit Testing Considerations. 
Table 1. Pre-visit Testing Considerations 
Consideration Explanation Control Procedure 
Standardized time to begin 
experimental visits 
Prevents influence of daily 
life on experimental data 
All experimental visits began 
between 06:00-08:00 
Prevention of vigorous 
physical activity before 
experimental sessions 
Reduces the temporary 
effects of vigorous exercise 
and recovery on the 
cardiovascular and 
cerebrovascular system on 
data 
Participants were sent a 
reminder email before their 
experimental visit reminding 
them to refrain from vigorous 
physical activity for 24 hours 
prior to testing 
Prevention of caffeine 
consumption 
Reduces the influence of 
caffeine on the 
cerebrovascular data. 
Caffeine is known to cause 
changes in arterial 
stiffening.106 
Participants were sent a 
reminder email before their 
experimental visit reminding 
them to refrain from caffeine 
or alcohol for 8 hours prior to 
testing 
Prevention of glycemic 
changes 
Reduces the influence of 
glycemic spikes during data 
collection 
Participants were sent a 
reminder email before their 
visit reminding them to 
refrain from eating 8 hours 
prior to testing 
Standardized amount of sleep 
between visits 
Prevents differences in sleep 
duration from confounding 
PWV, cognitive data 
Participants were asked about 





Internal validity can be maintained by ensuring consistent measurement practice and 
experimental procedure. All testing took place in the CML, which is a controlled environment at 
a comfortable temperature. Curtains can be used to isolate the lab from surprising stimuli offer 
the participant a safe testing environment. Prior to testing, investigators calibrated equipment 
regularly to ensure quality measurements. During testing, all continuous measurements were 
kept on the participant throughout the procedure, and all baseline and post measurements were 
performed in the supine position for consistently reliable measurements. Lastly, the non-
stimulating documentary that participants can watch was standardized, to ensure no variation due 
to mental stimulation. A summary of the described effects can be found below in Table 2. 
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Table 2. Controlled Variables. 
Table 2. Controlled Variables   
Criteria Method Rationale 
Ambient Temperature Thermometer check prior to 
testing 
Temperature could affect 
comfort level of participants 
Freedom from Unintended 
Stimuli 
Use of curtains during testing Unintended stimuli or noise 
could startle participant, 
changing hemodynamic and 
performance test results 
Standardized Documentary Download and save videos to 
use for every participant 
A non-stimulatory 
documentary can alleviate 
boredom for the participant, 





Screening interview Participants were asked about 
conformity to pre-assessment 




The population of study for this experiment would be healthy, young adults. “Healthy” is 
defined as free of cardiovascular disease, and “young” is defined as 18-45 years old. The age 
range for the participant sample was chosen because after age 45 in men and 55 in women, the 
cardiovascular system changes111. Therefore, this sample would minimize the influence of 
potential confounders on data due to age and cardiometabolic disease. At the conclusion of this 
research, specialized populations could be tested to determine the nuances of the physiological 
mechanism in that population. Specific inclusion and exclusion criteria are listed below in 
Tables 3 and 4 respectively. 
Table 3. Eligibility Criteria. 
Table 3. Eligibility Criteria   
Criteria Method Rationale 
Age 18-45 y Screening interview To ensure normal physiological 





Table 4. Exclusion Criteria. 
Table 4. Exclusion Criteria   
Criteria Method Rationale 
Currently pregnant Screening interview Pregnancy may affect ordinary 
cardiovascular function 
Current tobacco or nicotine user Screening interview Nicotine use affects the 
cardiovascular system 
Diagnosis of a cardiometabolic 
disease 
Screening interview Participants must be free of disease 
that may affect data on the 
cardiovascular system 
Currently taking medicine that 
affects cardiovascular function 
Screening interview Participants must be free of known 
alterations to cardiovascular 
function 
 
SEX AS A BIOLOGICAL FACTOR 
 
This study was not powered to assess sex differences. However, it could give a trend that 
would inform future experiments. Women who are experiencing or have experienced menopause 
were unable to participate in this study due to the related changes to their cardiovascular system. 
All women in either experimental trial underwent all testing during the follicular phase of their 
menstrual cycle, because estradiol levels were likely to be lowest.112 Estradiol is likely to be a 




Participants were not excluded or analyzed based on race or ethnicity. Furthermore, while 
health disparities in cerebrovascular diseases is documented,114 it is highly unlikely that this 
study has adequate power to ascertain racial and ethnic differences in the proposed mechanism. 
 
EXTERNAL VALIDITY / GENERALIZABILITY 
 
External validity can be maintained by constructing a sample that represents the 
population of interest. In this case, we were interested in assessing adults at the University of 
North Carolina at Chapel Hill. To do this, investigators sampled from students across the 
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university, so that the sample can match the school demographics as closely as possible. All 
studies balance external and internal validity measures, and this study is included. This study 
focuses on internal validity to establish consistent results of a mechanism, the function of which 




The question for this experiment is: “Does 1) hmPWV and 2) CBF change during an 
acute bout of prolonged sitting?” To answer this question, multiple statistical tests were 
considered. Paired t-tests or mixed-design Analysis of Variance (ANOVA) could have been used 
to compare values between pre and post treatment. T-tests would have been inadequate, as 
participants undergo multiple conditions with before and after measurements. A mixed-design 
ANOVA could have accommodate for multiple conditions, but would not have allowed for 
control of covariates, and not allowed for the full use of most of the measurements, most of 
which are continuous. A linear mixed model can accommodate for adjustment for covariates and 
can be used to analyze continuous data. It can also adjust for random and fixed effects.  In this 
study, fixed effects included within-subject fixed variables such as sex differences or differences 
due to height or body weight. Random effects could include the degree of arterial stiffening that 
is due to factors outside of the scope of the experiment, such as increased arterial stiffening not 
due to sitting that was occurring. The linear mixed model was used to observe differences in the 
primary outcome (hmPWV) and secondary outcomes (CBF, executive function assessment) 
between timepoints (pre/post) and between visits (CUFF or CONTROL) for each participant. 
Pearson’s correlation coefficients were be used to determine the relationships between each 
outcome in the study. Furthermore, Cohen’s d, a measure of effect size,115 was used to offer a 
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comparison of difference in means relative to sample variance. Mechanistic outcomes were used 
to guide discussion of the mechanism. 
 
POTENTIAL CHALLENGES & ALTERNATIVE STRATEGIES 
 
There were several potential challenges that could have arisen during the experiment. 
Specifically, there were numerous potential challenges that could have arisen due to the ongoing 
COVID-19 pandemic. For instance, human subject research could have been canceled at any 
time, indefinitely. To meet these potential challenges, some contingency plans were considered. 
A two-tiered strategy for recruitment would have helped address these challenges. The lying trial 
was planned to recruit six participants, and the prolonged sitting trial requires a minimum of 12 
participants to be adequately powered for conclusions of hmPWV. This number was inflated to 
16 to provide a buffer in the event of poor data quality or participant lost to follow up. The lying 
trial was conducted first due to the lower participant requirement. In the event of research 
cancellation during the sit trial, the results of the lay trial can stand alone as a pilot trial to inform 
future studies. Whereas beginning the sit trial first may have lead to under-powered results for 
the trial, and an inability to separate the effects of blood pooling from prolonged sitting. Once the 
lying trial is complete, the sit trial began. If the trial can reach 12 full participant data sets, then it 
would be adequately powered to make conclusions about arterial stiffening due to blood pooling. 
However, 16 participants would potentially increase data quality and external validity. 
 
Furthermore, the COVID-19 cancellation of human subject research made pilot testing 
impossible for a time. Depending on the size of the participant’s head, it may be difficult or 
impossible to fit the fNIRS and eye tracking glasses on simultaneously, and this could have been 
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considered in pilot testing. Once pilot testing was possible, testing to determine the feasibility of 
frontal lobe fNIRS and eye tracking was performed. While fNIRS monitoring of the occipital 
lobe would have been useful to track activity during the TMT, which is a visual task,101 it is 
unlikely to produce useful data during the VFT, which is a test with auditory stimuli. However, it 
would potentially have offered some useful data for executive function. 
 
There could have also been recruitment challenges related to external validity. If there 
was an abundance of research volunteers from a single sex, then participant selection would have 
been limited from that sex to include an even number of males and females. This would have 
maintained the external validity of the experiment. If no participants of one sex can be found, 
then an increase in participants from the opposite sex would have been considered for the study 
to be adequately powered. 
 
During data collection, equipment could have presented challenges also. It is possible that 
equipment could have failed or become unavailable. However, this experiment had several 
outcomes that could still inform the hypothesis if others failed. For example, while NIRS would 
show the most data for blood pooling in the calves, it is possible the machine could malfunction. 
For this reason, investigators took measurements of calf circumference pre/post sitting. 
Similarly, several outcomes were proposed that could show changes in the primary outcome 






Table 5. Project Timeline & Milestones. 
Table 5. Project Timeline & Milestones 
Activities Start Date End Date 
Pilot Testing August 2020 September 2020 
Equipment SOP’s current August 2020 September 2020 
Protocol/IRB  June 2020 August 2020 
Staff training August 2020 September 2020 
Study forms/ database June 2020 September 2020 
Set-up filling system (Onedrive) June 2020 June 2020 
Recruitment October 2020 February 2021 
Data collection October 2020 March 2021 
Aim 1 analysis March 2021 March 2021 
Aim 2 analysis March 2021 March 2021 
Hand Document to Committee March 2021 - 
Defend 2nd April 2021 - 
Respond to defense changes 3rd April 2021 12th April 2021 
Submit thesis to graduate school 13th April 2021 - 
Authorship order agreement 14th April 2021 May 2020 
Prepare Manuscript May 2021  
Milestones   
50% recruitment 1st Dec 2020  
100% recruitment 3rd March 2021  
100% data collection 7th March 2021  
Final database lock 10th March 2021  
100% data analysis  12th March 2021  
Submit Manuscript 13th April 2021  
 
SUMMARY 
WHY IS THIS STUDY NEEDED? 
 
• Acute bouts of prolonged sitting may contribute to arterial stiffening, and thereby 
atherosclerotic changes of the cerebral arteries. 
• The mechanism by which cerebral arterial stiffness occurs during prolonged sitting is 
unknown. 
• If the mechanism can be elucidated, the knowledge can be used to create treatment 
strategies that reduce arterial stiffening during bouts of prolonged sitting. 
WHAT IS KNOWN 
 
• Cerebral arteries become more stiff during a bout of prolonged sitting. 
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• Arterial stiffness causes dysfunction and damage to the vascular endothelium, resulting in 
remodeling. 
• During a bout of prolonged sitting, blood pools in the calf, causing local endothelial 
dysfunction and central hemodynamic changes. 
WHAT IS NOT KNOWN 
 
• It is unclear what is causing cerebral hemodynamic changes during a bout of prolonged 
sitting, and if and how much of the effect is related to blood pooling in the lower limbs. 
• The mechanism for changes in cerebrovascular function from prolonged sitting has not 
been established. This mechanism would include evidence for all contributing or related 
physiological steps between blood pooling and cerebrovascular changes. 
CRITICAL NEED 
 
• Evidence for influence of blood pooling on cerebral endothelial dysfunction would help 
design treatment strategies aimed at changing blood pooling behavior to reduce damages 
that to the cerebral arterial endothelium.  
• These could reduce the rate at which atherosclerotic changes occur. 
 
WHAT THIS STUDY ADDS 
 
• This study is the first to provide evidence of every feasibly measured step of the proposed 
mechanism. It is also the first to test multiple outcomes simultaneously, such as PWV and 
CBF, which reflect changes in arterial endothelial function, and executive function 
outcomes, which can show impairment of neurovascular coupling and offer a 
performative outcome related to cerebrovascular pathology. 
• Implications for future use: 
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o Future studies can investigate the role of this mechanism in specific populations, 
such as older adults or populations with cerebrovascular disease risks. 
o Treatment strategies for highly sedentary young people can potentially alter their 





CHAPTER III: METHODOLOGY 
 
This study is reported in accordance with CONSORT (Consolidated Standards of 
Reporting Trials) guidelines. Ethical approval was given by the Internal Review Board (IRB) of 




For the first cross-over trial, 6 participants of any gender were recruited. For the second, 
6 participants were recruited. To be included in the study, participants must have been aged 18-
45 years old. This age range was chosen to specifically observe changes related to the 
physiological mechanism in this study and minimize the influence of potential covariates on 
measurements. Participants were excluded for the following criteria: currently pregnant, current 
smoker or tobacco user, currently taking medicine that alters cardiovascular function, or 




The study consisted of two randomized cross-over trials, with two conditions each. One 
trial had prolonged sitting (SIT) or prolonged lying (LAY) to discern the effects of blood pooling 
versus the effects of an acute bout of sitting alone. In the SIT trial, participants sat in an upright 
position with knees bent for two hours for the Non-cuff condition; and prolonged sitting with a 
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venous pooling intervention (Cuff). Both conditions were held on an adjustable table that 
replicates a standard chair (Tiger Medical, TIGER#TM83695). The LAY trial had a Cuff and 
Non-cuff condition as well, but both were assessed while the participant was lying down. In the 
Cuff condition, participants sat in the same upright position, but have a standard blood pressure 
cuff (Hokansen, NJ, USA) inflated to sub-diastolic pressure proximal to the knee joint. Placing 
the cuff above the knee allowed for occlusion of the entire calf. Two hours of sitting time was 
selected because evidence indicates that at least an hour of prolonged sitting is needed to elicit 
significant cardiovascular disruptions.116,117 All visits started between 05:30 and 09:00 to reduce 
the influence of daily activities on the data. For each participant, the second condition visit was  
scheduled to begin within 30 minutes of the first condition visit, to control for diurnal variation 
(for a 09:00 first condition visit start time, a start time from 08:30 to 09:30 would be acceptable). 
Figures 4 and 5 depict the order of measurements and interventions for each visit in each trial. 
 




Figure 5. Measurement order for seated blood pooling randomized cross-over trial. 
 
VISIT 1: FAMILIARIZATION 
 
Participants interested in study participation were met in the Applied Physiology Lab 
(APL) to discuss the study. Participants who remained interested in participation after initial 
discussion were asked to complete a general medical questionnaire of health habits and medical 
history for the purpose of inclusion/exclusion criteria screening. Once screened, those eligible to 
were provided an informed consent form. The form included descriptions of all experimental 
devices and their use in the protocol, as well as how and when they were affixed to the 
participant for data collection. Participants were informed and asked to verbally confirm 
understanding of pre-testing guidelines. Following that, anthropometric data (height, weight, age, 
arterial path lengths, etc.) was collected by a member of the research team. Finally, the first study 
condition visit was scheduled, and the participant would leave for the day. The next visit was 




VISITS 2 & 3: EXPERIMENTAL VISITS 
 
Investigators met with the participant in the APL and confirmed that he or she followed 
pre-assessment guidelines. If the participant had not followed the guidelines, investigators would 
reschedule the visit with the participant. If the participant had followed the guidelines, he or she 
was escorted to the study area. 
 
Both protocols began with 20 minutes of rest in a supine position. While rested, the 
research team affixed NIRS probes to the skin superficial to the medial gastrocnemius. Doppler 
ultrasound was used to confirm correct placement of the probe according to manufacturer 
guidelines. The FinapresÒ NIBP device was placed on the participant’s non-dominant wrist. The 
FinapresÒ would provide continuous data throughout the procedure. Lastly, Doppler ultrasound 
was used to find the aortic notch, which was used for USCOM cardiac output monitoring. The 
devices would provide continuous data during the procedure. Then, the tourniquet leg cuff would 
be attached immediately superior to the knee joint, but not inflated. Transcranial Doppler (TCD) 
ultrasound data would be collected immediately to establish a baseline. Once the data was 
verified from each device, the tourniquet cuff was inflated to a sub-diastolic pressure of 80 
mmHg based on pilot data. This pressure was well tolerated by participants during pilot testing. 
Immediately after the supine rest time is complete and measurements are completed, participants 
were either left supine or moved to an upright seated position for 120 minutes. The measurement 
order for the supine and seated trials was randomized, and is visualized in Figures 3 and 4 
respectively, below. Participants would have the option to watch a low-stimulation nature 
documentary for the remainder of the sitting or supine period to minimize mental stimulation and 
discomfort but maintain wakefulness. 
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At the conclusion of the sitting time for either visit, the participant was laid supine if 
seated, and rested for 5 minutes. Then, TCD and CBF measurements were performed. Upon 
completion, the tourniquet cuffs were deflated and removed. After the cuffs were deflated, 
participants were administered the tests of executive function. During the tests, eye-tracking data 
was taken. At the conclusion of the experimental session, the research team scheduled the 
follow-up visit with the participant. The second visit was within 72 hours of the first visit. Figure 
6 shows the order of experimental conditions for each trial. 
 










PRIMARY OUTCOME: HEART-MCA PULSE WAVE VELOCITY (hmPWV) 
 
Acute arterial stiffening is a primary risk for atherosclerotic development. Therefore, an 
appropriate measure was needed to determine arterial stiffening. While some studies have 
associated aortic stiffness directly with changes to cerebral artery stiffness,15 other researchers 
have noted that this is not appropriate because the approach lacks specificity to the cerebral 
arteries.118 A method for assessment of cerebral arterial stiffness would need to be specific to the 
arteries that deliver blood to the brain. 
 
Heart-MCA pulse wave velocity (hmPWV) was measured using a continuous bilateral 
TCD (ST3, Spencer Technologies). The data was acquired continuously using an analog to 
digital convertor (Powerlab 30, ADInstruments). It is calculated as the time between the peak of 
the QRS complex on an electrocardiogram (ECG) and the peak of pulse velocity in the middle 
cerebral artery (MCA) divided by the pulse transit time of those two points. hmPWV is a novel 
technique for measuring cerebral arterial stiffness, so a clinically meaningful change in this 
parameter has not been established. Methods to assess cerebral arterial stiffness are new, with 
one of the first clinical trials to establish cerebrovascular disease risk being registered within the 
past year.119 
 
SECONDARY OUTCOME: CEREBRAL BLOOD FLOW 
 
MCA cerebral blood flow (CBF) was measured using Transcranial Doppler (ST3, 
Spencer Technologies). The data was acquired continuously using an analog to digital convertor 
(Powerlab 30, ADInstruments). An average value for blood flow velocity through the middle 
cerebral artery (MCA BFV) was used to assess changes in CBF continuously in both CUFF and 
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CONTROL conditions. For CCA CBF, pre and post measurements were taken using Doppler 
ultrasound, which was used to record CCA CBF (LOGIQ P6; GE Healthcare, Wauwatosa, USA) 
in both the CUFF and CONTROL conditions. At each measurement time, three (3) ten second 
videos of the CCA were recorded. The videos were processed using an imaging software (FMD 
Studio®, QUIPU, Italy) that generated data for both volumetric blood flow and shear rate on the 
arterial wall. Continuous results were compared over the duration of the sitting or supine period, 
and pre and post measurements were compared among time points and conditions (CUFF or 
CONTROL) in the SIT or LAY trials (4 measurements total per participant).  
 
Functional Near-Infrared Spectroscopy (fNIRS) was used to monitor regional changes in 
blood flow. fNIRS works by monitoring changes in oxygen metabolism. fNIRS can detect 
hemoglobin changes in the cerebral vasculature specifically, and can be used to determine 
cerebral perfusion rates for oxygen at different regions in the brain.120 Cerebral perfusion rates 
allow insight into healthy or impaired neurovascular coupling. A healthy brain can send a greater 
flow of oxygen-rich blood to active areas of the brain. To use fNIRS, sensors are placed on the 
surfaces of the scalp.  In this experiment, the frontal lobe is an area of interest, particularly 
during cognitive testing, as it is responsible for most of the executive function in the brain. To 
analyze the frontal lobe, sensors were placed just below or on the hairline.121 
 
SECONDARY OUTCOME: EXECUTIVE FUNCTION & COGNITIVE LOAD 
 
Executive function (EF) was tested through the use of the Trail Making Test (TMT)95 and 
the Verbal Fluency Test (VFT).96 The Trail-Making Test was divided into two parts: Part A and 
Part B. Only Part B was used in this study, as it is a better indicator of executive function.122 For 
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Part B, participants were presented with numbers and letters placed semi-randomly. The 
participant would then connect 25 numbers and numbers, alternating between numbers and 
letters in numerical or alphabetical order. For example, a participant would connect “1” to “A”, 
then connect “A” to “2”, and “2” to “B” until 25 symbols have been connected. Results from 
Part B were reported in “seconds to completion.” 
 
The VFT includes 2 parts as well: a test of semantic fluency and a test of phonemic 
fluency. For semantic fluency, participants were given 1 minute to name as many items as fit in a 
given category. For phonemic fluency, participants are given a letter, and must have stated as 
many words as they can that start with that letter in 1 minute. Both sections were scored in 
correct number of words stated. Times for the TMT were recorded by the software used and 
recorded to data sheets during testing, but VFT words were recorded during testing and analyzed 
after testing. The results of the VFT and the TMT were combined to make a value of EF. 
 
During both tests, relative cognitive load can be assessed with the use of eye-tracking 
goggles. Number of saccades and blink rate were tracked to determine the relative cognitive load 
of each test. Both the use of saccade counts and blink rate are validated methods to determine 
relative cognitive load of participants.101,102 Changes in cognitive load indicators during the 







INDEPENDENT VARIABLE: BLOOD POOLING 
 
Multiple methods were used to determine blood pooling. Calf circumference is a simple 
method to assess venous pooling in the calves, and NIRS offers continuous assessment via 
monitoring of hemoglobin concentration. Calf circumference measurements assess venous 
distension due to blood pooling. The measurement is based on the assumption that the volume of 
the calf tissue changed proportionally to the volume of blood pooling within the calf, and that the 
volume of calf tissue change was proportional to the change in calf circumference. Calf 
circumference was measured by assessing the total circumference change in the lower limb at the 
mid-gastrocnemius, which is often the widest part of the calf. A measuring tape was used to 
determine circumference, and the value recorded. After the baseline measurement, a marker was 
used to mark the measurement site. This was to allow exact replication for the measurement after 
sitting. Results were compared pre and post in the SIT or LAY trials, and for both the CUFF and 
CONTROL conditions (4 measurements total per participant).  
 
Near-Infrared Spectroscopy (NIRS) was used on the calf to determine oxygen 
metabolism rates. The NIRS instrument (Portalite, Artinis) uses non-ionizing light to detect 
oxygenated and deoxygenated hemoglobin in the vasculature, and can be used to determine 
perfusion rates for oxygen.74 The measurement of NIRS on the calf allowed us to determine 
venous pooling in the calf. Venous pooling can be observed when there is an increase in total 
hemoglobin in the tissue. Over time, a greater portion of the hemoglobin becomes deoxygenated 
hemoglobin, indicating that the tissue is absorbing oxygen, but not enough blood is leaving the 




MECHANISTIC OUTCOME: STROKE VOLUME AND CARDIAC OUTPUT 
 
A central factor of the proposed mechanism is a change in cardiac output. This can be 
detected non-invasively using the Finapres®, which can determine heart rate, stroke volume, and 
cardiac output using the Model method.105 Results can be acquired continuously, and can be 
measured throughout each testing session. Comparison of cardiac output over time helps to 
establish cardiac output as one of the changes that connect blood pooling in the calves with 
arterial stiffening changes in the cerebral arteries. While the Finapres® is validated and reliable 
for blood pressure monitoring,123 less work has been done to determine the validity and 
reliability of the device for testing cardiac output. 
 
Furthermore, stroke volume, and therefore cardiac output, can be measured using 
Doppler ultrasound as well.  Cardiac output monitoring using the USCOM 1 is a validated, non-
invasive method for measuring cardiac output.104 In this method, a Doppler ultrasound probe is 
placed on the chest, anterior to the aortic valve. The USCOM 1 software uses the detected flow 
velocity and cross-sectional area of the aortic valve to create a value for cardiac output. 
However, this method cannot be used continuously, and so was used during pre and post 




 Randomization for the experiment was performed using a public website 
(www.randomizer.org), which was used to assign groups to the Control or Cuff session first. The 
randomization protocol was performed by a member of the research team who was not a 
principal investigator. Due to the nature of the experiment, it was impossible to blind the 
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participant or the researcher to the ongoing experimental protocol. A research assistant would 




Sample size calculations were performed using G*Power 3.1 (Heinrich-Heine-Universität 
Düsseldorf, Germany). A conservative estimate for the primary outcome, hmPWV, using an ⍺-
level of 0.05, effect size of 0.25 (moderate effect), and power (1-β) of 0.8, generated a minimum 
sample size of 12 participants. For the SIT trial, the number was inflated to 16 to account for 




For a given outcome all measurement and analysis was conducted by a single observer. 
At the start of the study, the first three data sets were checked by an independent observer. A 
quality grading score was part of this over-reading so that protocol deviations could be detected. 
 
The TCD measurement of pulse wave velocity is continuous, and a minimum of 20 
seconds of data was collected at each measurement interval before and after treatments. During 
this time, care was taken to ensure minimal noise in the collected data. Similarly, all data for 
primary outcomes was assessed in triplicate to reduce intra-observer error. 
 
At the conclusion of the study, a random selection of 10% of the data sets (e.g., all data 




DATA MANAGEMENT AND STATISTICAL ANALYSIS 
 
During testing, data collection, and data analysis, participant information was tied to a 
unique identifier pertaining to the experiment and was anonymized to the individual participant. 
The identifier used the related experiment code and participant number (e.g. First participant 
would be VP01, etc.). Data management and analysis was completed using multiple software 
programs. Raw data collection was performed using Powerlab. Microsoft Excel (Excel, IN., 
Redmond, WA, USA) was used for data aggregation and organization. Analyses were performed 
using Jamovi v0.9. The α-level for the data was set a priori at α=0.05. Effect sizes were 
calculated using Cohen’s d, with 0-0.19 considered a trivial effect, 0.20-0.50 considered a small 
effect, 0.50-0.8 considered a moderate effect, and above 0.80 as a large effect. Missing data was 
filled in using mean substitution where appropriate or discarded. 
 
A mixed linear model was used to compare participants between experimental conditions 
and between time points. This method is well-suited for accommodating variance among 
multiple variables into a relationship and accounting for their effects. It can be used to assess 
relationships between variables while also adjusting for fixed or random effects. The mixed 
linear model can also help to show which variables have a moderating effect in a relationship. In 
this experiment, all measures of PWV were adjusted by blood pressure and age, which have been 








 Recruitment and testing of 6 participants in the SIT trial took place between February and 
April 2021. Out of the 6 participants recruited, 1 dropped out due to a vasovagal reaction (Figure 
7). Five participants (23.6 ± 5.3 years, 40% female, 23.1 ± 3.2 kg/m2) completed all experimental 




Figure 7. CONSORT Diagram for SIT and LAY Trials. 
 
Recruitment and testing of 6 participants in the LAY trial took place between January and 
March 2021. All 6 participants (26.5 ± 7.6 years, 4 females, 22.5 ± 2.3 kg/m2) completed all 
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One participant in the SIT trial had a vasovagal reaction while undergoing the CUFF 
condition in the SIT trial. The participant was dropped from the study. 
 
MANIPULATED OUTCOME: BLOOD POOLING 
SIT TRIAL 
 
Blood pooling, as measured by calf circumference, had a significant interaction effect 
between time and condition (ß = -1.26, 95% CI: -1.50 to -1.02, ES = 2.27; Figure 8). In the Non-
Cuff condition, calf circumference increased by 0.25% (ß = 0.088, 95% CI: -0.08 to 0.26, ES = 
0.19), whereas it increased by 3.69% in the Cuff condition (ß = 1.34, 95% CI: 1.15 to 1.51, ES = 
3.12). 
 
Figure 8. SIT trial calf circumference. Calf circumference is in units of centimeters. 
 
Cuff: ß = 1.34, 95% 
CI: 1.15 to 1.51 
Non-Cuff: ß = 0.088, 
95% CI: -0.08 to 0.26 
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Data from NIRS showed no significant interaction (p= 0.733), time, (p = 0.691) or 
condition effect (p = 0.230) in tHb. HHb had a nonsignificant interaction effect (p = 0.463) and 
nonsignificant time effect (p = 0.839), but did have a significant condition effect (ß = -18.35, 
95% CI: -33.07 to -3.634, ES = 0.43, p = 0.023). 
LAY TRIAL 
 
In the LAY trial, there was a nonsignificant interaction (p = 0.279) and time effect (p = 
0.143) and nonsignificant condition effect (p= 0.423) for calf circumference (Supplemental 
Figure 1). 
 
Using NIRS, there was a nonsignificant interaction (p = 0.643) and time effect (p = 
0.576) and a nonsignificant condition effect (p = 0.330) for tHb. HHb was found to have a 
nonsignificant interaction (p = 0.279) and time effect (p = 0.831) but did have a significant 
condition effect (ß = -12.72, 95% CI: -21.58 to -3.854, ES = 0.65, p = 0.010). 
 
PRIMARY OUTCOME: Heart-MCA PWV (hmPWV) 
SIT TRIAL 
 
 In both the Cuff and Non-Cuff conditions, hmPWV sharply decreased over time. There 
was a nonsignificant interaction effect (p = 0.856), and a large, significant main effect for time (ß 
= -97.17, 95% CI: -125.1 to -69.28, ES = 1.55) as well as a non-significant main effect for 




Figure 9. hmPWV results in the SIT trial. hmPWV, heart-middle cerebral artery pulse wave velocity (units of cm/s), presented as 




In both the Cuff and Non-Cuff conditions, hmPWV decreased over time. There was a 
nonsignificant interaction effect (p = 0.177), and a moderate, significant main effect for time (ß = 
-64.55, 95% CI: -110.9 to -18.24, ES = 0.39) as well as a non-significant main effect for 
condition (p = 0.670; Figure 10). Over time, hmPWV decreased by 42.36%. 





Figure 10. hmPWV results in the LAY trial. hmPWV, heart-middle cerebral artery pulse wave velocity (units of cm/s), presented 
as means with standard error. 
 
SECONDARY OUTCOME: Common Carotid Artery Cerebral Blood Flow (CCA-CBF) 
SIT TRIAL 
 
There was a large, significant interaction effect between time and condition (ß = 35.91, 
95% CI: 4.612 to 67.21, ES = 1.41; Figure 11) for CCA-CBF. Between conditions, CCA-CBF 
decreased 3.71% in the Cuff condition (ß = -5.68, 95% CI: -29.75 to 18.4, ES = 0.14), and 




increased 19.50% in the Non-Cuff condition (ß = 30.23, 95% CI: 6.16 to 54.3, ES = 0.76).
 





There was not a significant interaction (p = 0.962), time (p = 0.681), nor condition effect 
(p = 0.891) for CCA-CBF (Supplemental Figure 2). 
 
SECONDARY OUTCOME: EXECUTIVE FUNCTION TESTING AND EYE-TRACKING 
SIT TRIAL 
 
For each trial, cognitive tests were performed at the end of the familiarization visit for a 
baseline reading, and at the end of each experimental visit to obtain scores. For the Trail-Making 
Test (TMT), there were no significant differences between conditions (Base and Cuff, p = 0.652; 
Base and Non-Cuff, p = 0.741; Figure 12). However, the Verbal Fluency Test (VFT) showed a 
significant difference between the Base and the Non-Cuff condition (ß = 6.250, 95% CI: 1.533 to 
Cuff: ß = -5.68, 95% CI: 
-29.75 to 18.4 
Non-Cuff: ß = 30.23, 
95% CI: 6.16 to 54.3 
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10.97, ES = 0.62, p = 0.041). Between the Base and Non-Cuff condition, this was a 15.78% 
increase. There was no significant difference between the Base and Cuff condition scores for the 
VFT (p = 0.842). 
 
Figure 12. Trail-Making Test (TMT) scores across conditions, presented as means with standard error. 
 
 
Figure 13. Verbal Fluency Test (VFT) scores across conditions, presented as means with standard error. 
 
During each cognitive test, blink rate and pupil diameter were measured as well. 
However, no significant differences in blink rate or pupil diameter were observed across 



















































* = statistically 
significant difference 
at p = 0.05 level. 
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Table 6. Statistical data for blink rate measures in the SIT trial. 
  
Base to Cuff Base to Control 
Trail-Making 
Test 
p 0.28 0.275 
ß 2.41 2.44 
Verbal Fluency 
Test - Part 1 
p 0.356 0.767 
ß 6.4 2 
Verbal Fluency 
Test - Part 2 
p 0.386 0.428 




Table 7. Statistical data for pupil diameter measures in the SIT trial. 
  
Base to Cuff Base to Control 
Trail-Making 
Test 
p 0.998 0.566 
ß 0.006 -1.631 
Verbal Fluency 
Test - Part 1 
p 0.996 0.720 
ß 0.054 -3.943 
Verbal Fluency 
Test - Part 2 
p 0.825 0.962 




For the TMT, there were no significant differences between conditions at the p ≧	0.05 
level (Base and Cuff, p = 0.138; Base and Non-Cuff, p = 0.098; Supplemental Figure 3). There 
were also no significant differences between conditions of the VFT at the p ≧ 0.05 level (Base 
and Cuff, p = 0.138; Base and Non-Cuff, p = 0.098; Supplemental Figure 4). 
 
In terms of eye-tracking, no significant differences were detected in blink rate across any 
of the cognitive tests. There was a large, significant difference in pupil diameter between the 
Base and Cuff condition (ß = 10.82, 95% CI: 5.60 to 16.03, ES = 0.91, p = 0.011) during the 
second half of the VFT, which was a 42.19% increase from the Base condition to Non-Cuff. 
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There was no significant difference between the Base and Non-Cuff condition (Supplemental 
Figure 5). 
 
MECHANISTIC OUTCOME: fNIRS 
SIT TRIAL 
 
To assess changes in hemoglobin content across the frontal lobe during the experimental 
condition, changes in tHb and TSI% were assessed. There was a nonsignificant interaction (p = 
0.448) time (p = 0.107), and condition effect (p = 0.553) for tHb (Supplemental Figure 6). 
Similarly, there was a nonsignificant interaction (p = 0.379), time (p = 0.418), and condition 




There were nonsignificant interaction (p = 0.576) and time effects (p = 0.563), but there 
was a moderate, significant condition effect on tHb (ß = 3.005, 95% CI: 0.192 to 5.818, ES = 
0.72, p = 0.045; Supplemental Figure 7). For TSI%, there were nonsignificant interaction (p = 
0.340) and time effects (p = 0.268) for TSI%, and a nonsignificant condition effect (p = 0.051). 
 
MECHANISTIC OUTCOME: CARDIAC OUTPUT 
SIT TRIAL 
 
Cardiac output, as measured by the USCOM device, had an interaction effect that trended 
toward significance, but did not quite reach the p ≦	0.05 level (p = 0.057, ES = 0.34). There was 
a large time effect (ß = -0.395, 95% CI: -0.622 to -0.168, ES = 0.76; Figure 13) and a 









There was a nonsignificant interaction effect (p = 0.146), a moderate, significant time 
effect (ß = -0.475, 95% CI: -0.766 to -0.173, ES = 0.44), and a nonsignificant condition effect (p 
= 0.199; Figure 14). Over time, cardiac output decreased by 6.13%. 




Figure 15. Cardiac Output results from the LAY trial, presented as means with standard error. CO, cardiac output (units of 
L/min). 
 
MECHANISTIC OUTCOME: STROKE VOLUME 
SIT TRIAL 
 
Stroke volume, a component of cardiac output, was measured by the USCOM device. 




There were no significant interaction (p = 0.903), time (p = 0.981), or condition effects (p 
= 0.677) for stroke volume in the LAY trial. 
  
Time: ß = -0.475, 95% CI: -0.766 to -0.173 
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MECHANISTIC OUTCOME: HEART RATE 
SIT TRIAL 
 
Heart rate, a component of cardiac output, had a significant interaction effect between 
time and condition (ß = -10.06, 95% CI: -17.41 to -2.70, ES = 0.58; Figure 15). In the Cuff 
condition, heart rate decreased by only 4.46% (ß = -3.00, 95% CI: -8.51 to 2.51, ES = 0.24), 
whereas in the Non-Cuff condition, it decreased by 18.93% (ß = -13.06, 95% CI: -18.92 to -7.19, 
ES = 0.97). 
 




Heart rate, a component of cardiac output, did not have significant interaction (p = 
0.060), time (p = 0.115), nor condition effects (p = 0.112; Supplemental Figure 8).
Cuff: ß = -3.00, 95% CI: -8.51 to 2.51 
Non-Cuff: ß = -13.06, 95% CI: -18.92 to -7.19 
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CHAPTER V: DISCUSSION 
 
 
The primary aim of this study was to determine the role of venous pooling on cerebral 
arterial stiffening response during sitting. In the SIT trial, venous pooling was observed, 
particularly in the Cuff condition, which aligned with the hypothesis. There was a sharp decrease 
in hmPWV across all conditions in both trials, which ran counter to the hypothesis. Following 
that, secondary aims were to assess hemodynamic changes via CBF and functional changes in 
cognition that may accompany the arterial stiffening response. The Cuff condition was related to 
a significant decrease in CCA-CBF relative to the Non-Cuff condition. In addition, we found 
significant differences in scores for the VFT in the Cuff condition relative to the Non-Cuff 
condition in the SIT trial. Lastly, CO did change significantly with venous pooling, but appears 
to have been driven by changes in heart rate, rather than changes in stroke volume, as 
hypothesized. The main findings for the study were that hmPWV decreased over time, CCA-
CBF decreased with venous pooling, and a decreased CO did occur. 
LIMITATIONS AND STRENGTHS 
 
The limitations and strengths of the current study should be considered in evaluating the 
results. First, both trials (SIT and LAY) were only powered to detect changes in hmPWV. Some 
results that were close to, but not statistically significant at the p ≧ 0.05 level may have been 
affected, and further research with a greater sample size may detect different results. Second, the 
generalizability of this study may be limited due to a relatively homogenous population of 
young, healthy adults. With that in mind, this was deliberately chosen to minimize confounding 
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due to factors such as age and cardiometabolic disease. Third, there may have been a learning 
effect for both the TMT and VFT for executive function. While the order of conditions was 
randomized, the same type of test was used at each visit for consistency and could have 
influenced the results. 
Despite some limitations, this study has several strengths as well, such as novelty. This 
study is one of the first to use hmPWV to assess cerebral arterial stiffening. The use of hmPWV 
will provide a new measure to study the cerebral arteries non-invasively. Furthermore, several 
potential confounders were controlled for in this study, such as sleep, diet, and physical activity, 
that give this study robust internal validity. Lastly, the variety of measures used in data collection 
help show the multitude of physiological changes occurring in response to blood pooling at 
multiple timepoints in each condition. 
COMPARISON TO LITERATURE 
hmPWV 
 
Pulse wave velocity (PWV) is the gold standard non-invasive method for measuring 
arterial stiffness.125,126 While PWV techniques to measure central and peripheral arterial stiffness 
are common in the literature, techniques to study stiffness in the cerebral arteries are fairly novel, 
and currently being explored. In this study, hmPWV, which measures stiffness of the arterial 
segment between the aorta and the middle cerebral artery, decreased over all conditions, but had 
a relatively greater decrease while participants were seated rather than laying (Time effects: SIT: 
ES= 1.55; LAY: ES = 0.39). While there is sparse evidence for comparable results available, one 
study, using one of the closest examples of PWV techniques for evaluating cerebral arterial 
stiffness called carotid-cerebral PWV (ccPWV), noted that patients with cerebral arterial 
atherosclerosis (likely indicative of stiffer arteries) had a higher mean ccPWV value than those 
without.127 The responsiveness of hmPWV to different postural conditions in this experiment 
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may indicate that it is useful for future studies that seek to monitor differences in cerebral 
hemodynamic function. 
In contrast to these results, one of the few other studies to use hmPWV (Blackwell et al. 
2020), found a non-significant change in hmPWV in middle age adults after a 2 hour sitting 
bout.128 While the conditions between this study’s Non-Cuff condition and the sitting bout in 
Blackwell et al. were comparable, the study sample was different, as Blackwell et al. focused on 
middle-aged adults. The results could indicate that age is a factor that influences hemodynamic 




Results for a change in executive function were mixed. The only significant difference 
seen was between Base and Control conditions for the VFT in the SIT trial, and there were no 
significant differences seen in the TMT. It is possible these results show a potential learning 
effect for the VFT, that was eliminated in the Cuff condition. This would indicate that the Cuff 
condition (increased venous pooling) played a role in reducing an increase, that is, reduced 
scores relative to the Non-Cuff (control) condition. One study, using an attentional cognitive task 
assessment (SART test), showed a decrease in score associated with an increase in calf 
circumference (indicating venous pooling) after a bout of prolonged sitting, which agrees with 
these results.129 Furthermore, these results could have been related to the decrease in CCA-CBF 
that occurred in the Cuff condition of the SIT trial in this study. 
The proposed mechanism for this experiment stated that an increase in venous pooling 
would cause a decrease in cardiac output by way of decreased stroke volume, which would then 
increase hmPWV. While the results of this experiment did not show a relationship between 
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venous pooling and hmPWV, there was a drop in cardiac output with increased venous pooling. 
However, these changes appeared to be driven by changes in heart rate, rather than changes in 
stroke volume. While decreasing cardiac output has been reported in other studies that assess 
prolonged sitting,11 the mechanism for these changes is different from the proposed mechanism. 
 
A previous study (Stoner et al.) has shown no significant difference in a test of executive 
function (Stroop task) over the course of a sitting bout.130 While these studies differ in test 
methodology (Stroop vs. Trail-Making Test and Verbal Fluency Test), all three tests are valid in 
assessing different aspects of executive function.95,96,131 In particular, the TMT and Stroop tests 
rely on visual stimuli, whereas the VFT relies on auditory stimuli, which could have contributed 
to some of the observed differences. In our study and Stoner et al., there were minimal 
differences, as both studies used standardized sets of instructions was used at each test for 
consistency. However, both studies used healthy, young adults as a study population. There may 
have been minimal significant differences between conditions due to insufficient challenge to 
participants in the form of a ceiling effect. In normative data of participants performing the 
TMT, participants between the ages of 18-54 had faster scores than participants older than 54, 
followed by a generally linear increase in completion time with age.132 While the TMT is useful 
to diagnose dementias in older adults, participants younger than 54 may have completion times 
too low to observe the same changes even in the presence of altered neurovascular 
hemodynamics. Future studies may need to consider more complex cognitive tasks to elicit 







In both the SIT and LAY trials, venous pooling was increased in the respective Cuff 
condition. This study shows that occlusive cuffs can be used to effectively manipulate venous 
pooling. Increased venous pooling was not found to be related to decreases in hmPWV. 
However, changes in cognition as shown with the VFT, and changes in CBF, may be related to 
increased venous pooling. In populations such as older adults, who may be sensitive to acute 
reductions in CBF,80 strategies to acutely reduce venous pooling may help to mitigate effects on 
executive function in these populations. Reduced CBF can also potentially contribute to acute 
endothelial dysfuction,54 which may contribute to atherosclerosis with chronic exposure. 
Furthermore, future research could investigate the interaction between central and 
cerebral PWV measures over time. A paper by Yu et al.133 on the arterial stiffness gradient has 
shown that a combination of increasing central PWV and slight to no increases in peripheral 
measures of PWV (such as femoral-ankle PWV) in a sitting bout may be a useful indicator for 
pathogenic conditions. Increasing central PWV would indicate that pressure waves during 
systole are transferred farther, to more distal arteries and arterioles, exposing these blood vessels 
to greater pressure waves. If this phenomenon applies to the cerebral arteries, then an increasing 
central PWV combined with a decreased hmPWV as seen in this study could expose the cerebral 
arteries to high pressures waves. Exposure to higher pressure waves can be pathogenic to 
cerebral arteries.44 Since hmPWV decreased over time in this study, future studies could 








Table 8. Knowledge Summary. 
Table 8. Knowledge Summary  
What did we know? 
• Cerebral arterial stiffening has been reported with exposure to prolonged sitting. 
• Acute arterial stiffening exposes small arteries and arterioles to greater pressure waves, 
which can be potentially damaging. 
What did we not know? 
• The role of venous pooling on cerebral hemodynamic parameters such as arterial 
stiffening are not understood. 
What have we learned? 
• Cerebral artery stiffness at the middle cerebral artery does not seem to be related to 
venous pooling, but does seem to be related to changes in cardiac output. 
• Prolonged sitting, with additional venous pooling, seems to affect verbal executive 
function, which may be related to changes in CBF. 
Why is this new information useful? 
• Venous pooling could be a factor that decreases in CCA-CBF and verbal executive 
function, which means interruptions to prolonged sitting that focus on reducing venous 
pooling may help to preserve blood flow. 
What do we need to know next? 
• More information is needed on the aspects of prolonged sitting that affect cerebral 
arterial stiffness. 
• Future research could investigate the potential for relationships between cerebral arterial 
stiffness and central arterial stiffness. 
• Strategies to reduce venous pooling, and therefore reduce acute decreases in executive 
function and CBF, should be investigated for efficacy. 
• The findings in this study are likely generalizable to young, healthy adults, but can point 
to future research in specific populations at risk for acute changes in CCA-CBF (older 





 This study aimed to assess the role of venous pooling on cerebral hemodynamic status, 
which has been hypothesized to contribute to hemodynamic changes throughout the body, 
including the cerebral vasculature. To do this, we observed changes in hmPWV, CCA-CBF, and 
hemodynamic measures such as cardiac output to determine a potential mechanism for changes 
during a bout of prolonged sitting or laying. In doing so, we found that hmPWV may be a useful 
measure for looking at cerebral arterial stiffness. Separately, the VFT indicated potential 
cognitive changes related to venous pooling, that may be explained by a simultaneous decrease 
 
 65 
in CCA-CBF in the Cuff condition of the SIT trial. These data indicate that our proposed 
mechanism is incomplete, and more study is needed regarding the relationship between 
prolonged sitting and cerebral arterial stiffness.
 
 65 
APPENDIX A. CONSENT 
University of North Carolina at Chapel Hill  
Consent to Participate in a Research Study  
Adult Participants  
  
Consent Form Version Date: ______________  
IRB Study # 20-3403  
Title of Study: The Role Of Blood Pooling In The Legs During Prolonged Sitting On 
Cardiovascular And Cerebrovascular Outcomes: A Mechanistic Study  
Principal Investigator: Alexander Pomeroy  
Principal Investigator Department: Exercise and Sport Science  
Principal Investigator Phone number: (919) 962-0396  
Principal Investigator Email Address: alexpom@live.unc.edu   
Faculty Advisor: Lee Stoner  
Faculty Advisor Contact Information: (919) 962-0534  
  
CONCISE SUMMARY  
  
We are looking to examine the vascular, cerebrovascular, and executive function response to 
blood pooling in the veins of the lower limbs, a common side effect of prolonged sitting, with 
and without exposure to prolonged sitting itself. It is currently unknown whether (1) venous 
pooling has a role in systemic vascular health effects seen during prolonged sitting (2) 
whether venous pooling has a role in changes in blood flow to the brain and perfusion of the 
prefrontal cortex (3) whether venous pooling and the corresponding cerebrovascular changes 
affect executive function, and (4) what specific physiological pathways explain these 
changes. The devices used in this study are non-invasive and no known adverse events have 
occurred with use of the stated devices. The findings from this study may result in better 
understanding of how changes during prolonged sitting occur, and help elucidate potential 
strategies for reducing acute vascular, cerebrovascular, and cognitive dysfunction during 
prolonged sitting. The purpose of the study is to measure the changes in the heart, vasculature, 
brain perfusion and cognitive function caused by venous pooling in the legs from prolonged 
sitting.   
We seek healthy adults 18- 45 years of age, free of cardiometabolic disease, and who do not 
smoke nor vape. Pregnant women and those who take medications known to alter cardiovascular 
function are not eligible. A total time commitment of 305 min is required: the study consists of 
three visits, the first being a familiarization visit (45 min duration) and two experimental visits 
(130 min duration each).  
No significant risks will occur should you take place in this study. Your participation will benefit 
the scientific body on the changes that occur from prolonged sitting and venous pooling. There is 
no benefit to you for completing this study, however, we are happy to provide a summary of 
your results, including blood pressure, cardiac output, arterial stiffness, 
carotid blood flow, and cognitive measures, in comparison to group means after the completion 
of the study.  
What are some general things you should know about research studies?  
You are being asked to take part in a research study.  To join the study is voluntary.  
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You may choose not to participate, or you may withdraw your consent to be in the study, for any 
reason, without penalty.  
  
Research studies are designed to obtain new knowledge. This new information may help people 
in the future.   You may not receive any direct benefit from being in the research study. There 
also may be risks to being in research studies. Deciding not to be in the study or leaving the 
study before it is done will not affect your relationship with the researcher, your health care 
provider, or the University of North Carolina-Chapel Hill. If you are a patient with an illness, 
you do not have to be in the research study in order to receive health care.  
  
Details about this study are discussed below.  It is important that you understand this information 
so that you can make an informed choice about being in this research study.   
  
You will be given a copy of this consent form.  You should ask the researchers named above, or 
staff members who may assist them, any questions you have about this study at any time.  
  
What is the purpose of this study?  
The purpose of this research study is to (1) Explore the cardiovascular, cerebrovascular, and 
cognitive effects of venous pooling in the lower limbs during a bout of prolonged sitting, and (2) 
Explore the effects of venous pooling independently of prolonged sitting on cardiovascular 
function.  
  
Are there any reasons you should not be in this study?  
You should not be in this study if you have known cardiovascular or metabolic diseases (e.g. 
Congestive heart failure, peripheral artery disease, type I and II diabetes, etc.), 
you use tobacco or nicotine, take medications known to affect cardiovascular function (e.g. beta-
blockers, ACE inhibitors) or you are pregnant.  
  
How many people will take part in this study?  
Approximately 22 people at UNC-Chapel Hill will take part in this study.  
  
How long will your part in this study last?  
Should you wish to participate in the study, you will be required to attend the Applied 
Physiology Laboratory at University of North Carolina at Chapel Hill on three occasions. The 
first visit will last approximately 45 minutes, and the CONTROL and 
CUFF visits last approximately 130 minutes. 
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What will happen if you take part in the study?  
If you would like to take part in the study, you would be required to visit the Applied Physiology 
Laboratory at UNC, Chapel Hill on three occasions. See below for overall study design:  
Visit 1 - The first visit will be a familiarization session during which all experimental procedures 
will be described to you in full. You will provide informed consent before the study begins, then 
complete a brief questionnaire on your medical history to ensure you are eligible for this 
study. Pregnancy tests will be done on all females who might be able to get pregnant at the start 
of the study. The research team will pay for these pregnancy tests. If you meet the requirements, 
we will then show you how each device is prepared for this study, how it functions and where it 
will be placed on the body for data collection. At the conclusion of the visit, we will take your 
baseline cognitive assessment for the study. The following devices will be used for study 
purposes:   
• Transcranial Doppler (TCD) – A headset snugly placed on top of the head  
• VICORDER® – Non-invasive device using blood pressure cuffs to assess 
arterial health  
• Ultrasound Probe – Small probe lightly placed over several arteries 
running up the neck to assess blood flow to the brain  
• Near-Infrared Spectroscopy (NIRS) – Small probe (about 1 x 3 inches in 
size) placed on the calf  
• Functional Near-Infrared Spectroscopy (fNIRS) – set of 8 probes (each 
about 2 centimeters in diameter) mounted in a neoprene headcap  
• Non-invasive Blood Pressure cuff (NIBP) – Device wrapped around the 
wrist with small cuffs encircling the middle and index fingers  
• Equivital – Chest-worn device and strap that is placed on the skin under a 
shirt  
• USCOM – small, specialized doppler ultrasound that is pressed just above 
the suprasternal notch (approximately where the neck meets the sternum)  
• Pupil Core – eye-tracking device worn like eyeglasses  
This visit should take approximately 45 minutes.  
Visit 2 & 3 - During the experimental visits (CONTROL and CUFF), you will be required to rest 
quietly for a period of 10 minutes in a supine (lying) position. After, measures of cardiovascular 
function will be taken by the VICORDER® and Ultrasound devices. For the CUFF and 
CONTROL conditions, you will be asked to sit still and quietly for 2 hours while watching a 
non-stimulating documentary. Then, if seated, you will be passively shifted to a supine (lying) 
position where the VICORDER® and Ultrasound measurements will be taken again. At the end 
of the cardiovascular measurements in each experimental condition we will conduct a battery of 
cognitive tests.   
The cognitive tests involved in these two visits are called the Trail-Making Test (TMT) and the 
Verbal Fluency Test. In the TMT, you will complete two short puzzles on an iPad with your 
finger. You will be presented with numbers and letters placed semi-randomly. You will then 
connect 25 numbers and numbers, alternating between numbers and letters in numerical or 
alphabetical order. For example, one would connect “1” to “A”, then connect “A” to “2”, and “2” 
to “B” until 25 symbols have been connected. The VFT is a verbal test that also consists of 
two parts. In Part A, you will be given a category and instructed to name as many items in the 
categories as you can within 60 seconds. In Part B, you will be given a letter and will be asked to 
name as many words that begin with the letter as you can within 60 seconds.  
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Prior to attending the Lab for visits 2 & 3, you will have to perform the following pre-assessment 
guidelines:  
• Fasted (> 12 hours), consuming only water.  
• No caffeine consumption 12 hours prior to testing  
• No vigorous exercise 24 hours prior to testing.  
• No alcohol consumption 24 hours prior to testing.  
The total time commitment that will be required from you is approximately 305 minutes. 
Following the analysis of your data, we will happily provide a summary of your results in 
comparison to the group means.  
What are the possible benefits from being in this study?  
Research is designed to benefit society by gaining new knowledge.  You will not benefit 




What are the possible risks or discomforts involved from being in this study?  
The devices used in this study are non-invasive and there are no accounts of severe injury due to 
exposure to the stated devices. Physical harm due to participation in this study is likely very 
minimal:  
VICORDER® - The system requires the placement of pressure cuffs over several arteries for the 
collection of PWV/A data. Pressure cuffs will only be inflated underneath a level of 65 mmHg. 
Physical harm or discomfort is unlikely and include, but are not limited to:  
Risk 1: Discomfort/unease: Infrequent (1 – 10%) – Application of a slight pressure over the 
carotid artery may impose a sense of unease for the participant. However, the light pressure used 
for this experimental protocol will in no way significantly damage cardiovascular structure or 
place the participant in danger. Investigators will make certain that communication on the 
procedures during testing session are clearly conveyed to the participant for comfort and safety.   
Near-infrared spectroscopy (NIRS): Risk of injury or discomfort is extremely low due to this 
device. Possible physical harms are, but not limited to:  
Risk 1: Eye damage/irritation: Rare (<1%) – Please do not, at any point, stare into the light 
emitted from the NIRS probe  
Risk 2: Skin heating and irritation: Rare (<1%) – Wearing the NIRS probe for extended periods 
of time at once can theoretically lead to a warm feeling at the area where the probe is 
placed. However, this risk is minimal because the light emitted from this probe is not powerful 
enough to heat the skin. If you let the investigators know of any discomfort due to the probe, we 
will follow manufacturer guidelines to ensure the device is functioning correctly.  
Functional Near-infrared Spectroscopy (fNIRS): Risk of injury or discomfort is extremely 
low due to this device. Possible physical harms are, but not limited to:  
Risk 1: Mild headache: Infrequent (1 – 10%) – High quality data from this device requires 
the placement of the probes in a snug headcap over the forehead, superficial to the prefrontal 
cortex. The slight pressure applied to the area may be slightly discomforting and unusual.  
Risk 2: Eye damage/irritation: Rare (<1%) – Please do not, at any point, stare into the light 
emitted from the fNIRS probe.  
Risk 3: Skin heating and irritation: Rare (<1%) – Wearing the fNIRS probe for extended periods 
of time at once can theoretically lead to a warm feeling at the area where the probe is placed. 
However, this risk is minimal because the light emitted from this probe is not powerful enough 
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to heat the skin. If you let the investigators know of any discomfort due to the probe, we will 
follow manufacturer guidelines to ensure the device is functioning correctly.  
Transcranial Doppler (TCD): Data collection from this system requires the affixation of a 
headpiece to the participant. Risk of injury due to this device is extremely low. Possible harms 
may include, but are not limited to:  
Risk 1: Mild headache: Infrequent (1 – 10%)  – High quality data from this device requires the 
placement of the probe over the middle cerebral artery (MCA) and posterior cerebral artery 
(PCA). The slight pressure applied to the area may be slightly discomforting and unusual for the 
participant.  
  




What if we learn about new findings or information during the study?   
You will be given any new information gained during the course of the study that might affect 
your willingness to continue your participation.   
The imaging we are using in this research study is not the same quality as imaging that you may 
have as part of your health care. The images will not be reviewed by a doctor who normally 
reads such images (such as a radiologist). As a result, you may not be informed of any 
unexpected findings. The results will not be placed in your medical record.  Occasionally the 
technologist or principal investigator may notice something abnormal on the imaging.  If this 
does occur, the images will be reviewed by a qualified doctor to determine if there is anything 
of clinical importance. If something is found to be important then you, and/or your primary care 
provider will be notified.  Any further follow up and costs associated with the incidental finding 
will be your responsibility. There may be benefits to learning such results (such as early 
detection and treatment of a medical condition), but there are risks as well (such as problems 
with getting insurance or a job, or feeling worried about a finding for which no treatment is 
required or appropriate).  
   
Do you wish to be informed in case of clinical/relevant unexpected findings?  Please initial in the 
box below if you do not wish to be notified of clinical/relevant unexpected findings.  If you do 
not initial in the box, you will be notified of any findings.  
   
 ______ I do not wish to be notified.  
Will I receive any other clinical results?   
There are no other clinically relevant results of this research that will be communicated with 
you.  
  
How will information about you be protected?  
The data generated from this study will be used for the purpose of scholarly publication and 
potentially for research presentation. Your personal data will not be identifiable.   
However, there is an inherent risk for a breach of confidentiality due to the sharing of personal 
information with the research team for research purposes.   
Breach of confidentiality will be minimized by limiting the number of research team members in 
the laboratory during any testing session. By needing key card access to the laboratory, we are 
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limiting the number of individuals not on the research team who have access to the lab. Those 
who do have key card access are exercise physiology professors, PhD candidates, 
and Master’s candidates, and selected undergraduate students who are directly associated with 
the study and have performed all necessary trainings regarding sample handling, laboratory 
procedures, and confidentiality. All participants within the study are coded with an individual ID 
and no names will be identified in any document besides a master key document. This master 
key document will be kept in a locked drawer in the Cardiometabolic Laboratory within the 
Applied Physiology Laboratory.  
Participants will not be identified in any report or publication about this study.  We may use de-
identified data from this study in future research without additional consent.  
Although every effort will be made to keep research records private, there may be times when 
federal or state law requires the disclosure of such records, including personal information.  This 
is very unlikely, but if disclosure is ever required, UNC-Chapel Hill will take steps allowable by 
law to protect the privacy of personal information.  In some cases, your information in 
this research study could be reviewed by representatives of the University, research sponsors, or 
government agencies (for example, the FDA) for purposes such as quality control or safety.  
Recordings will be taken of verbal responses during the cognitive assessment to clarify scores for 
data analysis. Once data is successfully recorded into the data spreadsheet, the audio recording 
will be destroyed. Audio recording files will be kept less than 1 week in total. Audio recordings 
are not required, but will help researchers to better record cognitive data.  
Recordings of the space in front of you will be made using Pupil Core. These videos may include 
parts of your body such as your hands, if held up close to the face. These videos are a 
requirement of the study.  
Check the line that best matches your choice:  
  
_____ OK to record me during the study  
  
_____ Not OK to record me during the study  
  
What will happen if you are injured by this research?  
All research involves a chance that something bad might happen to you.  If you are hurt, become 
sick, or develop a reaction from something that was done as part of this study, the researcher will 
help you get medical care, but the University of North Carolina at Chapel Hill has not set aside 
funds to pay you for any such injuries, illnesses or reactions, or for the related medical care.  Any 
costs for medical expenses will be billed to you or your insurance company.  You may be 
responsible for any co-payments and your insurance may not cover the costs of study related 
injuries.  
If you think you have been injured from taking part in this study, call the Principal Investigator at 
the phone number provided on this consent form.  They will let you know what you should do.   
By signing this form, you do not give up your right to seek payment or other rights if you are 
harmed as a result of being in this study.  
What if you want to stop before your part in the study is complete?  
You can withdraw from this study at any time, without penalty.  The investigators also have the 
right to stop your participation at any time. This could be because you have had an unexpected 
reaction, or have failed to follow instructions, or because the entire study has been stopped.  
  
If you withdraw or are withdrawn from this study all data collected up until the point of 
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withdrawal will be retained, however no additional information will be collected unless you 
provide additional written permission for further data collection at the time of your withdrawal.   
Will you receive anything for being in this study?  
You will not receive anything for taking part in this study.  
  
Will it cost you anything to be in this study?  
It will not cost you anything to be in this study.   
What if you are a UNC student?  
You may choose not to be in the study or to stop being in the study before it is over at any time.  
This will not affect your class standing or grades at UNC-Chapel Hill.  You will not be offered or 
receive any special consideration if you take part in this research.  
What if you are a UNC employee?  
Taking part in this research is not a part of your University duties, and refusing will not affect 
your job.  You will not be offered or receive any special job-related consideration if you take part 
in this research.  
  
What if you have questions about this study?  
You have the right to ask, and have answered, any questions you may have about this research. If 
you have questions about the study (including payments), complaints, concerns, or if a research-
related injury occurs, you should contact the researchers listed on the first page of this form.  
  
  
What if you have questions about your rights as a research participant?  
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject, or if you 
would like to obtain information or offer input, you may contact the Institutional Review Board 
at 919-966-3113 or by email to IRB_subjects@unc.edu.  
Page Break   
Participant’s Agreement:  
  
I have read the information provided above.  I have asked all the questions I have at this time.  I 
voluntarily agree to participate in this research study.  
  
______________________________________________________  




Printed Name of Research Participant   
  
______________________________________________________  









Signature of Witness if applicable; e.g. literacy issues,  
visually impaired, physically unable to sign, witness/interpreter for  
non-English speaking participants using the short form)  










APPENDIX B. SUBJECT PRE-ASSESSMENT INSTRUCTIONS 
 
Hello,  
This is a reminder email of your appointment at the Cardiometabolic Lab for “The Role of Blood 
Pooling In The Legs During Prolonged Sitting On Cardiovascular and Cerebrovascular 
Outcomes: A Mechanistic Study,” on ______ at______.  The following pre-visit criteria must be 
met prior to your familiarzation/experimental visit:  
  
For familiarization visits (Visit 1):  
• Abstain from alcohol 12 hours prior  
• Abstain from caffeine 12 hours prior  
• Wear comfortable clothes to the visit, such that your calves can be exposed easily  
• If applicable, wear a sports bra for comfort and assess for ECG and skin temperature 
readings  
The familiarization visit to is expected to last approximately 45 minutes.  
 
Please fill out the COVID-19 screening survey prior to each visit, either by scanning the QR 
code on the lab door upon arrival or filling out this link 
here: https://unc.az1.qualtrics.com/jfe/form/SV_9FxzSKmV2ezrU69  
 
The Cardiometabolic Lab is part of the Applied Physiology Lab, located in the basement of 
Fetzer Hall. From the front entrance, go straight past Gym A and down the stairs on the right. 
From the bottom of the stairs, move down the hall in the direction of the Student Recreation 
Center (SRC). Before moving up the ramp to the SRC, turn left and look for the sign for Applied 
Physiology Lab on the right. Make this right turn and you will find a small lobby to the lab on 
the left, where you will be greeted by a member of the Cardiometabolic Lab.  
 
If you have trouble finding the location, please call or text Katie at 919-360-7515 or Alex at 585-




APPENDIX C. SUPPLEMENTAL DATA 
 
INTRODUCTION TO SUPPLEMENT 
 This supplement contains data from both trials performed for further observation. The 
LAY trial was an exploratory trial, and therefore figures from this trial not depicting data directly 




Supplemental Figure 1. LAY trial calf circumference by condition, presented as means with standard error. Calf circumference 
is in units of cm. 
Abbreviations: Pre, experimental timepoint before prolonged sitting; Post, experimental timepoint after 120 minutes of 
prolonged sitting; cuff, occlusive cuff condition; non-cuff, control condition. 
 







Supplemental Figure 2. CCA-CBF in the LAY trial, presented as means with standard error (units of ml/min). 
Abbreviations: BFMean, equivalent to CCA-CBF; 0, experimental timepoint before prolonged sitting; 120, experimental 
timepoint after 120 minutes of prolonged sitting; cuff, occlusive cuff condition; non-cuff, control condition. 
 









Supplemental Figure 3. Trail-Making Test results in the LAY trial. 
Abbreviations: Base, initial measurement taken immediately after familiarization; cuff, occlusive cuff condition; non-cuff, 
control condition. 
 































Supplemental Figure 4. Verbal Fluency Test in the LAY trial. 
Abbreviations: Base, initial measurement taken immediately after familiarization; cuff, occlusive cuff condition; non-cuff, 
control condition. 
 
Interpretation: There were no significant differences between results from the Verbal Fluency Test (TMT) over the course of 
























Supplemental Figure 5. Pupil diameter during LAY Verbal Fluency Test part 2 (VFT2), presented as means with standard error. 
Abbreviations: Base, initial measurement taken immediately after familiarization; cuff, occlusive cuff condition; non-cuff, 
control condition. 
 
Interpretation: Pupil diameter significantly increased between the base and cuff conditions in the LAY trial. Greater pupil 































Supplemental Figure 6. fNIRS results in the SIT trial, presented as means with standard error. 
Abbreviations: tHb, total hemoglobin; TSI%, tissue saturation index; 0-10, change between baseline and 10 minutes which was 
used as baseline measure; 0-120, change between baseline and 120 minutes; 0-60, change between baseline and 60 minutes; cuff, 
occlusive cuff condition; non-cuff, control condition. 
 
Interpretation: There were no significant interaction, time, or condition effects for tHB over the SIT trial. There were also no 
significant interaction, time, or condition effects for TSI% in the SIT trial. 
 
 
Supplemental Figure 7. fNIRS results in the LAY trial, presented as means with standard error. 
Abbreviations: tHb, total hemoglobin; TSI%, tissue saturation index; 10, change between baseline and 10 minutes which was 
used as baseline measure; 60, change between baseline and 60 minutes; 120, change between baseline and 120 minutes; cuff, 
occlusive cuff condition; non-cuff, control condition. 
 
Interpretation: There were no significant interaction or time effects for tHb in the LAY trial, but there was a significant 
condition effect (ß = 3.005, 95% CI: 0.192 to 5.818, ES = 0.72, p = 0.045) for tHB over the LAY trial. However, there were no 






Supplemental Figure 8. Heart rate data from the LAY trial, presented as means with standard error. 
Abbreviations: HR, heart rate; Pre, experimental timepoint before prolonged sitting; Post, experimental timepoint after 120 
minutes of prolonged sitting; cuff, occlusive cuff condition; non-cuff, control condition. 
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